C4 Therapeutics director awarded 2,650 shares
Anderson Kenneth Carl reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Anderson Kenneth Carl reported acquisition or exercise transactions in this Form 4 filing.
C4 Therapeutics, Inc. director Kenneth C. Anderson received an equity award of common stock rather than cash fees for his board service. On July 1, 2026, he was granted 2,650 shares at a value based on the closing market price of $4.34 per share, in line with the company’s Non-Employee Director Compensation Policy. Following this compensation grant, Anderson directly holds 71,950 common shares. Additional shares are held indirectly through several Anderson family revocable and irrevocable trusts, for which he disclaims beneficial ownership except for any pecuniary interest.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 2,650 | $4.34 | $12K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (7)
- F1. These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.
- F2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 1, 2026.
- F3. Shares held by the Kenneth C. Anderson 2021 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- F4. Shares held by the Kenneth C. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- F5. Shares held by the Cynthia E. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- F6. Shares held by the Kenneth C. Anderson Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- F7. Shares held by the Cynthia E. Anderson Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Key Figures
Key Terms
Non-Employee Director Compensation Policy financial
Revocable Trust financial
Irrevocable Trust financial
pecuniary interest financial
Grant, award, or other acquisition financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did C4 Therapeutics (CCCC) director Kenneth C. Anderson report in this Form 4?
Does this C4 Therapeutics (CCCC) Form 4 show any open-market purchases or sales by Kenneth C. Anderson?
AI-generated analysis. How Rhea-AI works. Not financial advice.